Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the Viral Entry Inhibitor PRO 542

Viral entry inhibitors represent an emerging mode of therapy for human immunodeficiency virus type 1 (HIV-1) infection. PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates. PRO 542 binds to the viral surface glycoprotein...

Descripción completa

Detalles Bibliográficos

Publicado en:	Antimicrob Agents Chemother
Autores principales:	Jacobson, Jeffrey M., Israel, Robert J., Lowy, Israel, Ostrow, Nancy A., Vassilatos, Linda S., Barish, Melanie, Tran, Diep N. H., Sullivan, Brian M., Ketas, Thomas J., O'Neill, Tobias J., Nagashima, Kirsten A., Huang, Wei, Petropoulos, Christos J., Moore, John P., Maddon, Paul J., Olson, William C.
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	American Society for Microbiology (ASM) 2004
Materias:	Antiviral Agents
Acceso en línea:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC321533/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/14742190/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.48.2.423-429.2004
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!